In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.
In vivo administration of interleukin-2 (IL-2)-secreting tumor cells results in complete protection against persistent infection by Theiler's murine encephalomyelitis virus (TMEV) in susceptible DBA/2 mice. The IL-2-mediated protection was found to depend on the inoculum size as well as the timing of IL-2 administration. IL-2-treated and TMEV-infected mice displayed a three- to fourfold relative increase in virus-specific cytotoxic T-lymphocyte (CTL) precursors. Thus, we postulate that the persistence of TMEV infection in susceptible mice reflects limited numbers of relevant CTL precursors and their time course of induction and activation.
Larsson-Sciard
E L
EL
Unité des Virus Lents, URA 1157, Centre National de la Recherche Scientifique, Paris, France.
Dethlefs
S
S
Brahic
M
M
D000818:Animals; D002478:Cells, Cultured; D007376:Interleukin-2 / Q000008:administration & dosage*; D051379:Mice; D008811:Mice, Inbred DBA; D012367:RNA, Viral / Q000032:analysis; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*; D017945:Theilovirus / Q000235:genetics / Q000276:immunology*
D007376:Interleukin-2; D012367:RNA, Viral